European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The standard of care for patients with recurrent ovarian cancer is platinum-based combination chemotherapy for those who relapse more than six months after completing adjuvant therapy. The use of biological agents such as bevacizumab has increased progressionfree survival (PFS), but has not shown a significant increase in overall survival (OS). Immunotherapy treatment modality is being actively pursued for patients with ovarian cancer. The goal of immunotherapy is to generate a tumor specific, T cell response that decrease residual disease, and protects against future recurrence. Combination therapy of anti-PD-1 antibodies, and anti-CTLA-4 antibodies reverses the TIL dysfunction and induces tumor regression in solid tumors, including ovarian cancer. When GM-CSF vaccine is added, it results in increased tumor rejection.